Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gamma-aminobutyric acid transporter 3 (GAT-3, SLC6A11) is a sodium- and chloride-dependent membrane transporter primarily expressed in astrocytic processes throughout the brain, notably in the cerebral cortex and globus pallidus[2][1][7]. It mediates high-affinity uptake of GABA—the major inhibitory neurotransmitter in the central nervous system—removing GABA from the synaptic cleft and thus regulating both the magnitude and duration of inhibitory neurotransmission[1][2][4][7]. By rapidly clearing GABA, GAT-3 helps maintain synaptic precision and prevent spillover-mediated tonic inhibition. Differential regional expression and selective function in glia distinguish GAT-3 from other GABA transporters. The transporter has been implicated in pathology, including alcohol dependence, and is an emerging target for neurological and addiction-related drug development[3][5].
Reuptake blockade: Inhibitors increase extracellular GABA by blocking GAT-3-mediated reuptake into astrocytes[1][5] Enhanced GABAergic tone may decrease excitability in certain brain regions
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid transporter 3 (GAT-3).